All In Biotech

Drug Trial Radar · NCT07306949

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

A Multicenter, Open-Label, Single Arm, Post-Marketing Clinical Study to Evaluate the Therapeutic Effects of Acoramidis Hydrochlorideon Cardiac Biomarkers and Current Clinical Features in Patients With Transthyretin-type Cardiac Amyloidosis: The CARE ATTR Study

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.

Conditions

  • Transthyretin-type Cardiac Amyloidosis

Interventions

  • AcoramidisDrug

    Participants will receive acoramidis tablets orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Progression Rate as Measured by N-terminal pro-brain-type Natriuretic Peptide (NT-proBNP) and/or Outpatient Diuretic Intensification (ODI)Time frame: Baseline through 12 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bunkyō City, Japan · Not yet recruiting

  • Research Site

    Bunkyō City, Japan · Not yet recruiting

  • Research Site

    Kumamoto, Japan · Not yet recruiting

  • Research Site

    Kurume-shi, Japan · Recruiting

  • Research Site

    Kyoto, Japan · Not yet recruiting

  • Research Site

    Mitaka-shi, Japan · Not yet recruiting

  • Research Site

    Nagoya, Japan · Not yet recruiting

  • Research Site

    Nankoku-shi, Japan · Not yet recruiting

  • Research Site

    Okayama, Japan · Not yet recruiting

  • Research Site

    Ōtsu, Japan · Not yet recruiting

  • Research Site

    Sagamihara-shi, Japan · Not yet recruiting

  • Research Site

    Sapporo, Japan · Not yet recruiting

  • Research Site

    Shinjuku-ku, Japan · Not yet recruiting

  • Research Site

    Suita-shi, Japan · Not yet recruiting

  • Research Site

    Tsu, Japan · Not yet recruiting

  • Research Site

    Yufu-shi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.